Sharma East India Hosp And Medical Research Ltd vs Thyrocare Technologies Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: Oct 31, 2026

Key Highlights

The Latest Trading Price of Sharma East India Hosp and Medical Research Ltd is ₹ 80 as of 29 Oct 15:30 . The P/E Ratio of Sharma East India Hosp and Medical Research Ltd changed from 0 on March 2021 to 0 on March 2026 . This represents a CAGR of 0.0% over 6 yearsThe P/E Ratio of Thyrocare Technologies Ltd changed from 42.2 on March 2021 to 34.2 on March 2026 . This represents a CAGR of -3.44% over 6 years The Market Cap of Sharma East India Hosp and Medical Research Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2026 . This represents a CAGR of 0.0% over 6 yearsThe Market Cap of Thyrocare Technologies Ltd changed from ₹ 4774 crore on March 2021 to ₹ 5566 crore on March 2026 . This represents a CAGR of 2.59% over 6 years The revenue of Sharma East India Hosp and Medical Research Ltd for the Sep '26 is ₹ 0 crore as compare to the Jun '26 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of Thyrocare Technologies Ltd for the Sep '26 is ₹ 275.24 crore as compare to the Jun '26 revenue of ₹ 244.88 crore. This represent the growth of 12.4% The ebitda of Sharma East India Hosp and Medical Research Ltd for the Sep '26 is ₹ 0 crore as compare to the Jun '26 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of Thyrocare Technologies Ltd for the Sep '26 is ₹ 48.74 crore as compare to the Jun '26 ebitda of ₹ 82.13 crore. This represent the decline of -40.66% The net profit of Sharma East India Hosp and Medical Research Ltd changed from ₹ 0 crore to ₹ 0 crore over 10 quarters. This represents a CAGR of 0.0% The net profit of Thyrocare Technologies Ltd changed from ₹ 23.94 crore to ₹ 15.22 crore over 10 quarters. This represents a CAGR of -16.57% The Dividend Payout of Sharma East India Hosp and Medical Research Ltd changed from 0 % on March 2021 to 0 % on March 2026 . This represents a CAGR of 0.0% over 6 yearsThe Dividend Payout of Thyrocare Technologies Ltd changed from 110.36 % on March 2021 to 149.75 % on March 2026 . This represents a CAGR of 5.22% over 6 years .

About Sharma East India Hosp and Medical Research Ltd

Sharma East India Hospitals & Medical Research Limited was incorporated on November 16, 1989.
The Company is engaged in providing medical and healthcare services and real estate services and is presently running a multi-specialty hospital in the name of 'Jaipur Hospital' at Lal Kothi, at Rajasthan since 1989. As far as the achievements of the Company are concerned, the first assessment of the Company was conducted by National Accreditation Board for Hospitals and Health Care Providers (NABH), NABH accreditation system is one of the methods for commitment to quality enhancement throughout whole of the health care system in India.
It involves all professional and service groups to ensure that high quality in health care is achieved, while minimizing the inherent risks associated with modern health care delivery.

About Thyrocare Technologies Ltd

Thyrocare Technologies Limited was incorporated in January, 2000.
The Company operates in the healthcare industry and is involved in providing quality diagnostic services at affordable costs to patients, laboratories and hospitals in India. As of 31 March 2025, the Company offered more than 920 distinct tests that support early detection, preventive care and the ongoing disease monitoring.
Their 43 profiles are administered under its reputed 'Aarogyam' brand, which offers patients a suite of wellness and preventive health care tests.
The Company primarily operates its testing services through a fully automated Centralised Processing Laboratory (the CPL) and has expanded its operations to include a network of Regional Processing Laboratories (RPLs).
The company currently operates 25 RPLs, one in each of New Delhi, Coimbatore, Hyderabad, Kolkata, Bangalore, Bhopal, Mumbai Patna and Chennai, which process samples sourced from their respective regions.

FAQs for the comparison of Sharma East India Hosp and Medical Research Ltd and Thyrocare Technologies Ltd

Which company has a larger market capitalization, Sharma East India Hosp and Medical Research Ltd or Thyrocare Technologies Ltd?

Market cap of Sharma East India Hosp and Medical Research Ltd is 26 Cr while Market cap of Thyrocare Technologies Ltd is 7,273 Cr

What are the key factors driving the stock performance of Sharma East India Hosp and Medical Research Ltd and Thyrocare Technologies Ltd?

The stock performance of Sharma East India Hosp and Medical Research Ltd and Thyrocare Technologies Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Sharma East India Hosp and Medical Research Ltd and Thyrocare Technologies Ltd?

As of October 31, 2026, the Sharma East India Hosp and Medical Research Ltd stock price is INR ₹80.0. On the other hand, Thyrocare Technologies Ltd stock price is INR ₹457.0.

How do dividend payouts of Sharma East India Hosp and Medical Research Ltd and Thyrocare Technologies Ltd compare?

To compare the dividend payouts of Sharma East India Hosp and Medical Research Ltd and Thyrocare Technologies Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.